|Bid||89.02 x 0|
|Ask||89.19 x 0|
|Day's Range||89.40 - 89.40|
|52 Week Range||74.50 - 94.09|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Yahoo Finance’s Alexis Keenan reports the latest on vaccination mandates and bans on vaccination proof.
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningfulFindings provide further evidence that sutimlimab results in rapid inhibition of C1-activ
Chris Meekins,Raymond James Healthcare Policy Analyst, joins Yahoo Finance Live to break down what went well and poorly during the COVID-19 pandemic and how to better prepare for possible future pandemic.